Technavio, a tech-focused market research firm, has published a new report on the global infantile spasms therapeutics market, which is expected to grow at a CAGR of more than 2% during the forecast period 2017-2021.
Based on geographical segmentation, Technavio market researchers categorize the global infantile spasms therapeutics market into the following key regions: the Americas, APAC, and EMEA.
Click here to request a free sample of this report
Top three contributors for the global infantile spasms therapeutics market are elaborated below
Infantile spasms therapeutics market in the Americas: The Americas is expected to retain its position as the dominant revenue generating segment of the global infantile spasms therapeutics market during the forecast period. The growth of the market is likely to be fueled by the incentives for developing orphan drugs and the high return on investment (ROI). The implementation of the Orphan Drug Act 1983 in the US is also an incentive for market growth as it allows companies to avail incentives for R&D purposes.
According to Barath Palada, a lead analyst at Technavio, specializing in research on cardiovascular and metabolic disorders, “The US is the single largest regional market in the infantile spasms drugs market in the Americas. The CDC estimated that the incidence rate of epilepsy in the US is approximately 2,000 cases per year. It was also reported that the total direct and indirect cost associated with epilepsy and its related diseases is almost USD 16 billion annually.”
Infantile spasms therapeutics market in EMEA: The market for infantile spasms therapeutics market in EMEA is projected to experience growth at a slow pace during the forecast period. Factors such as assistance from regulatory bodies and the exemption from pricing constraints are expected to be the driving forces behind the market’s growth.
Infantile spasms therapeutics market in APAC: The infantile spasms therapeutics market in APAC is expected to grow at a faster pace in comparison to the Americas and EMEA due to the increased awareness of the disease, leading to increased uptake of drugs. By 2021, the infantile spasms therapeutics market in APAC is anticipated to account for a revenue of almost USD 38 million.
Ask an analyst to know more about this report
The top vendors operating in the global infantile spasms therapeutics market are:
- H. Lundbeck
- Mallinckrodt Pharmaceuticals
- INSYS Therapeutics
Other prominent vendors in the market include Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, and Valerion Therapeutics.
A more detailed analysis is available in the Technavio report titled, ‘Global Infantile Spasms Therapeutics Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Cancer Monoclonal Antibodies Market 2017-2021
- Global Artificial Pancreas Devices System Market 2016-2020
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
